Research Article

BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells

Kamisha T. Woolery,¹ Mai Mohamed,¹ Rebecca J. Linger,¹ Kimberly P. Dobrinski,¹ Jesse Roman,² and Patricia A. Kruk¹,3,4

¹Department of Pathology & Cell Biology, University of South Florida, Tampa, FL 33612, USA
²Department of Medicine, University of Louisville, Louisville, KY 40202, USA
³Department of Obstetrics & Gynecology, University of South Florida, Tampa, FL 33612, USA
⁴H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA

Correspondence should be addressed to Patricia A. Kruk; pkruk@health.usf.edu

Received 20 November 2014; Accepted 17 June 2015

Academic Editor: Seiichi Saito

Copyright © 2015 Kamisha T. Woolery et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Ovarian cancer (OC), an inflammation associated cancer, is the deadliest gynecologic malignancy and is the 9th most common cancer among women [1]. Approximately 22,240 new cases are diagnosed and 14,030 women die of the disease annually [1]. Since most OC are diagnosed in late stage, the 5-year survival is approximately 27% [1].

Most OCs are epithelial ovarian carcinomas traditionally thought to arise from the ovarian surface epithelium (OSE) [2]; though more recently, studies have suggested that OC may arise from the fallopian tube epithelium [3, 4]. The etiology of the disease is not completely understood, but family history (FH) is the strongest risk factor for the development of epithelial OC [5]. Hereditary OCs are often associated with mutation of the tumor suppressor breast cancer susceptibility gene 1 (BRCA1) [6]. Carriers of the BRCA1 mutation have a 30% risk of developing OC during their lifetime [7]. BRCA1 plays a role in DNA damage response, cell cycle signaling, recruitment of chromatin modifying proteins, interaction with transcription factors, and ubiquitin ligase activity [8]. Loss of these functions may contribute to the development of cancer by promoting genomic instability and accumulation of cancer-causing mutations. Mutation of the BRCA1 gene can also result in either “loss of function” or “gain of function” with appearance of novel truncated protein products, respectively (reviewed in [9]). Among possible gain-of-function BRCA1 mutations, the 185delAG mutation is one of the most common founder mutations and is associated with a 66% lifetime risk of developing OC [10].

The 185delAG BRCA1 truncated mutant, BRAT, is the result of a deletion of two nucleotides in the second exon of the BRCA1 gene leading to a reading frame shift and a premature stop codon at position 39. Previously, we...
demonstrated that human OSE cells with the BRAT mutation exhibited enhanced apoptosis and caspase-3 activation [11] as well as diminished levels of phosphorylated Akt, cellular inhibitor of apoptosis 1 (cIAP1), and X-linked inhibitor of apoptosis protein (XIAP) [12]. We also found that BRAT-mediated maspin expression was correlated with enhanced chemo-sensitivity [13] which is in agreement with clinical reports of increased survival in patients with elevated maspin levels [14]. Microscopic examination of ovarian specimens obtained following prophylactic oophorectomy from women with FH of OC indicated that greater than 85% presented with two or more abnormal OSE histologic features such as surface epithelial pseudostratification, surface papillomatosis, cortical invaginations of OSE, epithelial inclusion cysts, and epithelial hyperplasia [15]. Likewise, overtly normal OSE from women with a FH of breast and/or OC (FHOSE) in culture show an increased autonomy of the epithelial phenotype in terms of expression of the epithelial differentiation marker CA125 [16], persistence of an epithelial morphology [16], and reduction in epithelial-mesenchymal conversion as noted by the maintenance of high keratin expression, but a reduction of collagen type II expression compared with no family history (NFH) OSE [17]. Since OSE become more committed to an epithelial phenotype in the course of carcinogenesis, these reports coupled with our previous findings suggest that preneoplastic characteristics may already exist in overtly normal OSE in some women with a strong FH of breast and ovarian cancer.

Inflammation of the ovarian epithelium has also long been associated with increased risk for OC [18–21]. By promoting a local pelvic inflammatory reaction, endometriosis has been associated with increased risk for endometrioid adenocarcinoma and clear cell carcinoma of the ovary [22–25]. Likewise, chronic pelvic inflammatory disease, often resulting from infection, also supports a role for inflammatory traumatization in the development of OC [26, 27]. Lastly, epidemiological studies suggest that incessant ovulation causes rapid cycles of OSE division associated with repeated ovulatory traumatization and repair of the ovulatory defect [28]. Ultrastructural and histochemical studies of OSE in situ have shown that OSE migrates and proliferates extensively during repair of the OSE after ovulation [29, 30]. During ovulatory repair, OSE is exposed to proinflammatory mediators such as cytokines, chemokines, matrix-remodeling enzymes, and various growth factors that can result in an increased risk for malignant transformation [31, 32]. Reports of OC associated with ovarian hyperstimulation due to fertility drugs [33, 34] further support a role for inflammatory traumatization in OC.

Interleukin-1 beta (IL-1β) is a proinflammatory cytokine mainly produced by monocytes and macrophages [35], but which can also be produced by endothelial cells, fibroblasts, and epidermal cells in response to bacterial or innate immunity stimulation [36]. Interestingly, normal and malignant epithelial ovarian cells also produce IL-1β [2]. IL-1β is translated into a 31 kDa inactive precursor form that is cleaved intracellularly by caspase-1 into an active 17 kDa secreted form [35]. The aim of this study was to investigate the in vitro production of IL-1β in human OSE cell lines carrying the 185delAG BRCA1 mutation in order to determine whether enhanced IL-1β in these cells could contribute to an inflammatory phenotype.

2. Materials and Methods

2.1. Cell Culture and Transfection. The following SV 40–Large T-Antigen transfected human OSE (IOSE) cell lines were used: IOSE118 derived from a normal patient with a FH of breast and/or OC with wtBRCA1 status confirmed [13]; IOSE 121 derived from a normal patient with NFH of breast and/or OC though BRCA1 mutation status was not determined; and IOSE 3261-77 and IOSE 1816-86 derived from normal patients with a FH of breast and/or OC as well as confirmed carriers of the BRCA1 185delAG mutation. IOSE cells were cultured in Medium 199/MCDB 105 (Sigma, St. Louis, MO) with 10% fetal bovine serum (FBS) and gentamicin. Stable PCDNA (pcDNA3.1) and BRAT clones (BRATc1, BRATc2) were generated by transfection of 2.5 × 10^5 IOSE I18 cells with 2.5 μg of pcDNA3.1 or Flag-BRAT with G418 resistance gene as previously described [13] using Program X-005, Kit V, and the Nucleofector device (Amaxa/Lonza, Walkersville, MD). Stable cells were maintained in 1 mg/mL G418 selection media and BRAT clones were confirmed to express BRAT by RT-PCR [13]. All cells were incubated at 37 °C with 5% CO₂. For knockdown studies, cells were cotransfected with 1.5 μg ON-TARGETplus siRNA (siCREB, siCON) from Dharmacon (Chicago, IL). For treatment with IL-1 receptor antagonist (IL-1ra), stable BRAT clones were washed with phosphate buffered saline (PBS) and media containing 0.1% FBS were added to the cells along with varying concentrations of IL-1ra (R&D Systems, Inc., Minneapolis, MN). After 6 hours, the media were removed and RNA was extracted from the cells for PCR analyses as described below.

2.2. Western Immunoblot. Cells were washed in PBS, trypsinized, pelleted, and washed 1-2 times in cold PBS. Cells were lysed for 30 minutes on ice in modified CHAPS buffer, and the lysate was centrifuged at 115,000 × g for 1 hour. Then 30 μg of protein was separated via 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene fluoride (PVDF) membranes, dried, and blocked in 5% milk in Tween 20-Tris buffered saline. Blots were incubated in their respective primary antibodies overnight, followed by incubation with a horseradish peroxidase- (HRP-) conjugated secondary antibody (Fisher, Pittsburgh, PA), and developed via enhanced chemiluminescence substrate (ECL) (Pierce/Fisher, Pittsburgh, PA). Antibodies used were IL-1β (1:1000) Cat. # 2022 (Cell Signaling Technology, Beverly, MA), Actin clone AC-40 (1:10,000) Cat. # 4700 (Sigma, St. Louis, MO), Apoptosis-associated Speck-like protein containing a C-terminal caspase recruitment domain (ASC) (1:1000) Cat. # sc-271054 (Santa Cruz Biotechnology, Inc., Dallas, TX), Caspase-1 (1:1000) Cat. # 2225 (Cell Signaling Technology, Beverly, MA), CREB (1:1000) Cat. # 9104 (Cell Signaling Technology, Beverly, MA), phospho-CREB (1:1000) Cat. # 9196 (Cell Signaling Technology, Beverly, MA), NACHT, LRR, and PYD domains-containing
protein 3 (NALP3) (1:1000) Cat. # sc-134306 (Santa Cruz Biotechnology, Inc., Dallas, TX). Western blot quantification was done by ImageJ software normalizing band strength to the respective actin band.

2.3. Enzyme-Linked Immunosorbant Assay. For conditioned media (CM) analyses, medium containing 0.1% FBS was added to cells 24 hours after transfection/plating. After 24 hours, cells were counted and CM were collected and centrifuged to remove debris, aliquoted, and stored at (−80°C). For the IL-1β Enzyme-Linked Immunosorbant Assay (ELISA), CM were also concentrated 17x using Amicon Ultra-15 Centrifugal Filter Unit with Ultracel-10 membrane (Millipore, Billerica, MA) before storage at 80°C. To analyze the presence of mature IL-1β, an ELISA (R&D Systems, Inc., Minneapolis, MN) was performed on concentrated CM samples in triplicate according to the manufacturer’s protocol. Fluorescence was read on an ELx800 Absorbance Microplate Reader (Biotek, Winooski, Vermont) using Gen5 Data Analysis Software (Biotek, Winooski, Vermont). Resultant values were derived from a standard curve and expressed as the mean IL-1β concentration of triplicate samples ± standard error. When cell viability varied significantly, IL-1β concentration was normalized to average cell number at time of CM collection.

2.4. Polymerase Chain Reaction. RNA samples were isolated using TRIzol reagent from Invitrogen (Carlsbad, CA) as per the manufacturer’s protocol and DNase-treated.

For BRAT semi-quantitative PCR to confirm transfection, 1μg total RNA, oligo(dT), and reverse transcriptase were used to generate single-strand cDNA as previously described [13]. The cDNA samples were amplified using the Applied Biosystems GeneAmp RNA PCR Core Kit (Foster City, CA). Primers used were Flag-BRAT sense (CGATGACAAAATGGATTTATCTGC), Flag-BRAT antisense (GAGACAGGT-TCCCTTCTCAACTCC), actin sense (GGGAATTCAAAA-CTGGGAAACGGTTGAGG), and actin antisense (GGAAGC- TTATCAAGATGCTCGGCCACA). The amplified products were electrophoresed on a 10% polyacrylamide gel, stained with SYBR Green (Lanza, Rockland, ME), and photographed with the Kodak EDS 120 Digital Analysis System. The net intensity of each band was normalized to the respective endogenous control band.

For quantitative PCR, 100 ng total RNA was reverse-transcribed to generate single-strand cDNA as previously described [13]. The cDNA samples were amplified in triplicate using Fast SYBR Green Master Mix (Applied Biosystems GeneAmp RNAPCR Core Kit (Foster City, CA)) followed by incubation at 95°C for 1 minute and 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 1 minute. The amplified products were electrophoresed on an agarose gel, stained with SYBR Green (Lanza, Rockland, ME), and photographed with the Kodak EDS 120 Digital Analysis System. The net intensity of each band was normalized to the respective endogenous control band.

For quantitative PCR, 100 ng total RNA was reverse-transcribed to generate single-strand cDNA as previously described [13]. The cDNA samples were amplified in triplicate using Fast SYBR Green Master Mix (Applied Biosystems GeneAmp RNAPCR Core Kit (Foster City, CA)) followed by incubation at 95°C for 1 minute and 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, and 72°C for 1 minute. The amplified products were electrophoresed on an agarose gel, stained with SYBR Green (Lanza, Rockland, ME), and photographed with the Kodak EDS 120 Digital Analysis System. The net intensity of each band was normalized to the respective endogenous control band.

2.5. Dual-Luciferase Assay. Stable I18 pcDNA3.1 or BRAT clones were transfected with 0.15μg Renilla luciferase reporter and 1.5μg IL-1β luciferase promoter deletion constructs pIL1(4.0 kb)LUC (−4000), pIL1(3.1 kb)LUC (−3100), pIL1(1.8 kb)LUC (−1800), pIL1(0.9 kb)LUC (−900), and pIL1(0.5 kb)LUC (−500). Twenty-four hours later, cells were collected in Promega Passive Lysis Buffer and subjected to two freeze-thaw cycles. Lysates were centrifuged at 10,600 ×g for 1 minute at 4°C, and the supernatant was collected. Luciferase activity was assessed in triplicate using a manual luminometer and the Promega Dual Luciferase Assay System according to the manufacturer’s protocol. For knockdown reporter studies, siRNA was cotransfected and cells were collected 48 hours after transfection.

2.6. Immunoprecipitation. Cells from stable I18 pcDNA3.1 and BRAT clones were washed with PBS and incubated on ice with RIPA lysis buffer containing protease inhibitors. After 15 minutes, the cells were removed by scraping, the lysates were incubated for 60 minutes on ice, and then the lysates were centrifuged at 10,000 ×g for 10 minutes at 4°C. Two micrograms of primary antibody was incubated with 1 mg of whole cell lysate for 2 hours at 4°C. Protein A/G agarose suspension was added to lysate and antibody mixture followed by incubation at 4°C on a rocker overnight. The suspension was collected by centrifugation at 500 ×g for 2 minutes at 4°C. The pellet was washed with RIPA buffer containing protease inhibitors followed by analysis by western immunoblotting.

2.7. Statistics. For real-time PCR, relative gene expression was expressed as the average fold change (RQ) of RQmin and RQmax calculated as 2−(ΔΔCt×T×SD(ΔCt)) and 2−(ΔΔCt×T×SD(ΔCt)), respectively, at the 95% confidence interval, for 5 degrees of freedom and where SD = standard deviation, T = confidence level and Ct = cycle threshold. For ELISA and reporter assays, Student’s t-tests were performed to assess statistical difference between means of triplicates ± standard error from three separate experiments.

3. Results

3.1. IL-1β Levels Are Increased in IOSE Cells Carrying the BRCA1 185delAG Mutation. To determine the relationship between the BRCA1 185delAG mutation and protein levels of IL-1β, we compared IL-1β protein levels in human OSE cell lines that endogenously carry this mutation to those with wild-type BRCA1. Both FH IOSE 3261-77 and 1816-686 cell lines with confirmed 185delAG mutation had 7-fold and ≥13-fold higher active IL-1β protein levels, respectively, as measured by western blot than the NFH cell line (IOSE-121) (Figure 1(a)). Likewise, 3261-77 and 1816-686 cell lines had 2- and 10-fold, respectively, higher levels of secreted IL-1β protein in their CM as measured by ELISA than the IOSE-121 cell line (Figure 1(b)).

3.2. BRAT Transfection Increases Levels of IL-1β. To confirm that increased intracellular and secreted IL-1β levels are related to the presence of BRAT, we analyzed IOSE-118 cells.

BioMed Research International 3
stably transfected with PCDNA or Flag-BRAT for IL-1β message and protein levels. BRATc1 had approximately 3-fold higher levels of IL-1β RNA as measured by real-time PCR than the pcDNA3.1 cell line (Figure 2(a)). Furthermore, densitometric analyses indicated that 22% of cellular pro-IL-1β in BRAT cells was cleaved into its active form while only 5.5% of cellular pro-IL-1β in pcDNA3.1 cells was cleaved into its active form (Figure 2(b)). Lastly, BRATc1 and BRATc2 both had 2-fold and 1.5-fold, respectively, higher levels of secreted IL-1β protein levels as measured by ELISA than the pcDNA3.1 cells (Figure 2(c)).

3.3. BRAT-Mediated IL-1β Promoter Activity Is Partially Mediated by CREB. To determine which region of the IL-1β promoter was required for the BRAT-mediated IL-1β promoter activation, we utilized dual-reporter assays in BRAT cells using five truncated IL-1β promoter luciferase reporter plasmids. There was no difference in reporter activity between deletion constructs (−4000), (−3100), and (−1800) (Figure 3(a)). However, reporter activity was diminished by 80% between deletion constructs (−1800) and (−900) (Figure 3(a)) suggesting that the 900 bp region between the (−1800) construct and the (−900) construct contributes to BRAT-mediated IL-1β promoter activity.

To further evaluate BRAT-mediated IL-1β promoter activation, we performed an online transcription factor prediction analysis of the 900 bp promoter region identified earlier to determine potential transcription factor binding sites using the prediction software, PROMO [37, 38]. Our analyses identified two potential CREB binding sites within the 900 bp promoter region. Further, densitometric analyses of western immunoblots performed for phospho-CREB and CREB levels revealed 30% increased levels of phospho-CREB in BRAT cells (Figure 3(b)). Based on this observation, we used pooled siRNA to knockdown CREB and western blot to confirm CREB silencing. We found that CREB knockdown resulted in partial loss of IL-1β promoter activity using the (−1800) reporter plasmid (Figure 3(c)).

3.4. Caspase-1, ASC, and NALP3 Protein Levels Are Increased in BRAT Cells. To confirm intracellular cleavage of the inactive IL-1β into its active form, we measured caspase-1 levels, the known intracellular activator of IL-1β. Stably transfected pcDNA3.1 cells had about 3-fold more inactive precursor caspase-1 protein levels than BRAT cells as seen by western blot (Figure 4(a)). However, stably transfected BRAT cells showed up to a 50-fold increase in active caspase-1 by western blot (Figure 4(a)). Given that BRAT might increase IL-1β activation by caspase-1-mediated cleavage, we sought to determine if the NALP3-ASC inflammasome, which cleaves pro-caspase-1 into its active form, was enhanced in BRAT cells. Western immunoblots confirmed a 3-fold increase of ASC protein levels in BRAT cells compared to the pcDNA3.1 cells (Figure 4(b)). Likewise, immunoprecipitation followed by densitometric analyses showed that, when normalized to cellular protein, both ASC and NALP3-bound ASC protein levels were 44% and 250% higher, respectively, in BRAT cells (Figure 4(c)).

3.5. IL-1Ra Suppresses Proinflammatory Mediators in BRAT Cells. To evaluate the potential autofeedback loop of IL-1β on OSE cells, we treated stably transfected BRAT-containing IOSE cells with the IL-1 receptor antagonist, IL-1Ra. Then, we measured mRNA expression levels of known IL-1β downstream transcription targets: IL-1β, IL-6, and IL-8 by real-time PCR. Treatment of BRAT cells with IL-1Ra resulted in up to a 50% loss of mRNA expression levels of IL-1β, IL-6, and IL-8 (Figure 5).

4. Discussion

The results of the present study show that the 185delAG BRCA1 mutant protein, BRAt, increases IL-1β mRNA and protein levels in immortalized human OSE cell lines. Interestingly, compared to controls, increased levels of IL-1β varied among IOSE cell lines and may reflect differences in BRCA1
Figure 2: IL-1β protein and message levels are increased in stably transfected BRAT cells. (a) Cells stably expressing BRAT or the pcDNA3.1 cells were plated at equal densities and RNA was isolated, DNase-treated, and reverse-transcribed. Real-time PCR was performed in triplicate for IL-1β and actin using SYBR Green detection and the data are expressed as the mean fold difference ± standard error. (b) pcDNA3.1 and BRATc1 cells were analyzed for precursor (pro-) and cleaved IL-1β protein expression via western blot. Blots were then stripped and probed for β-actin as a loading control. Values represent relative densitometry. (c) pcDNA3.1, BRATc1, and BRATc2 cells were plated in triplicate at similar densities and conditioned media were collected. IL-1β ELISA activity assay was performed in triplicate and the data are expressed as the mean ± standard error. Symbol (⁎) denotes statistical significance at the 0.01 confidence level between BRAT and PCDNA3.1 cells.

185delAG penetrance, BRAt expression, and/or wtBRCA1 expression [11, 13]. Therefore, it is important to note that inherent differences of wtBrca1 expression among cell lines derived from patients endogenously carrying the 185delAG mutation can limit understanding the independent functions of BRAt in these cells. For these reasons, we transitioned our studies into transiently or stably transfected 185delAG cell lines in a confirmed wtBRCA1 background.

We also demonstrated that BRAT-dependent expression is transcriptionally mediated, in part, via CREB binding sites. In addition, we found that BRAT-dependent activation of IL-1β protein by caspase-1 may be enhanced by increased expression of the NALP3-ASC inflammasome. While further investigation is required to discover the exact mechanism of enhanced NALP3-ASC protein expression in BRAT cells, we suspect that ASC expression may be CREB-dependent or API-dependent since the current and prior studies indicate BRAT-mediated gene expression through CREB and API sites [39]. Further, CREB binding sites are likely present in the ASC promoter according to commercially available promoter ChIP assay (Qiagen, Valencia, CA) program analysis. Lastly, we confirmed that IL-1β plays a role in expression of proinflammatory mediators, IL-6 and IL-8, via the IL-1 receptor suggesting that BRAT might stimulate a proinflammatory environment that could promote OC oncogenesis.

Establishing animal and cell models of OC oncogenesis has proven to be difficult. Spontaneous development of OC in animal models occurs with a low frequency and highly variable phenotypes [40]. Furthermore, OC lacks a clear molecular profile making it difficult to elucidate a universal cause in OC initiation or progression [41–43]. Loss of some or all wild type functions of the BRCA1 gene product due to gene mutation is commonly associated with enhanced breast cancer and OC risk (reviewed in [9]). BRCA1 gene
Figure 3: CREB sites within the IL-1β promoter partially mediate enhanced IL-1β mRNA expression in BRAT cells. (a) Cells stably expressing BRAT were transiently transfected with the indicated IL-1β deletion reporter constructs and a Renilla constitutive luciferase reporter plasmid for normalization. Lysates were collected, subjected to two freeze-thaw cycles, and assayed in triplicate on a manual luminometer using Promega’s Dual Luciferase Assay Kit. Luciferase activity was normalized to Renilla luciferase activity for each triplicate, averaged, and results are expressed as mean reporter activity ± standard error. (b) Stable BRAT (white bars) and pcDNA3.1 (grey bars) cells were analyzed by western immunoblot for comparison of cellular levels of phospho-CREB, CREB, and actin. The results are expressed in relative densitometric units. (c) Cells stably expressing BRAT cells were cotransfected with nontargeting control siRNA (siCon) or siRNA targeting CREB, collected, and assayed similarly to (a). Protein lysates were collected in parallel for knockdown analyses and CREB protein silencing demonstrated by western blot (inset). Symbol (*) denotes statistical significance ≤ 0.03 confidence level.

mutations resulting in a premature stop codon are generally susceptible to nonsense-mediated messenger RNA (mRNA) decay. However, two common risk-associated BRCA1 mutations, 185delAG and 5382InsC, were found to be unaffected by mRNA decay [44, 45]. This study utilizes a stable OSE cell line model with intact endogenous biallelic BRCA1 along with the 185delAG BRCA1 mutant transcript. By retaining a BRCA1 wild type background, we are able to conclude that changes observed are due to the presence of the 185delAG BRCA1 mutation and not due to the partial or complete loss of BRCA1. This is in keeping with previous studies that have shown other BRCA1 mutations with independent and novel gain-of-function roles in OC proliferation, chemosensitivity, tumorigenesis, and apoptosis [46, 47].

Inflammation has long been suggested to contribute to tumor initiation, promotion, and progression [48]. Many components of the inflammatory pathway, including free radicals, cytokines, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and vascular endothelial growth factor (VEGF) have been implicated in the development of various malignancies, including OC [49]. Immunohistochemical analyses revealed increased COX-2 expression in nonmucinous ovarian tumors and increased COX-2 expression correlating with poor prognosis [50]. Likewise, the present results are in keeping with others who reported a relation between proinflammatory mediators and increased OC risk. A case-control study by Clendenen et al. confirmed a positive association between circulatory inflammatory cytokines, IL-2, IL-4, IL-6, IL-12, and IL-13, and OC risk [51]. Also, increased serum levels of the inflammatory marker CRP have been associated with an increased risk of OC [20, 52]. Yellapa et al. demonstrated increased expression of the proinflammatory cytokine, IL-16, in serum and tissue of early and late stage OC patients as well as increased IL-16 serum levels during the progression from normal to early and late stage OC progression in hens [53]. Further, since increasing IL-16 serum levels preceded detection of OC by transvaginal ultrasound, it is tempting to speculate that monitoring proinflammatory mediators, such as IL-1β, may signal disease in women at high risk for OC before detection by conventional means.

Epidemiological studies suggest that long-term usage of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased OC risk [54–56]. Further, in vitro and in vivo use of phytochemicals [57] exert anti-inflammatory activity related to reduced OC progression by stabilizing
**Figure 4**: BRAT alters levels of inflammasome constituents. (a) Cells stably expressing pcDNA3.1 or BRAT (BRATc1 and BRATc2) were analyzed for precursor (pro-caspase-1) and cleaved caspase-1 (caspase-1 p20) protein levels via western blot. Blots were then stripped and probed for β-actin as a loading control. Values represent relative densitometric units. (b) Stable pcDNA3.1 or BRATc1 cells were analyzed for ASC protein expression via western blot. Blots were then stripped and probed for β-actin as a loading control. Values represent relative densitometric units. (c) Lysates obtained from stable pcDNA3.1 and BRATc1 cells were immunoprecipitated with ASC antibody and then analyzed via western blot for ASC and NALP3. Values represent densitometric units.

**Figure 5**: IL-1Ra inhibits IL-1β, IL-6, and IL-8 mRNA expression in BRAT cells. Cells stably expressing BRAT were plated at equal densities, treated with recombinant IL-1Ra, and collected. RNA was isolated, DNAse-treated, and reverse-transcribed. Real-time PCR was performed in triplicate from two separate experiments for IL-1β, IL-6, IL-8, and actin using SYBR Green detection. Data are expressed as the mean fold change in gene expression ± standard error.
p53 [58], enhancing cisplatin sensitivity [59], inhibiting cell growth and VEGF expression [60], and suppressing IL-6 function [61]. There are currently three IL-1 inhibitors used in the treatment of nonmalignant inflammatory conditions: recombinant IL-1Ra, anakinra; IL-1 trap, rilonacept; and monoclonal anti-IL-1β antibody, canakinumab [62]. Consequently, premalignant targeting of the proinflammatory mediator IL-1β and its upstream processors, caspase-1 and/or the NALP3 inflammasome, specifically in 185delAG BRCA1 mutation carriers, may reduce the risk of malignant transformation initiated by chronic inflammation.

Lastly, tumors can develop within and in response to their inflammatory microenvironment. For example, Kim et al. observed localized IL-1 expression among normal, benign, and malignant canine mammary tumors such that IL-1 could not be detected in normal tissue while concentrated IL-1 expression was noted in the stroma of benign tumors and diffuse expression in malignant and metastatic tumors [63]. Similarly, IL-1β secreted by OC cells suppresses p53 expression in cancer-associated fibroblasts [64]. In OC, IL-1β also promotes invasiveness and tumor angiogenesis and induces immune suppression [65]. Constitutive production of IL-1β by human ovarian carcinoma cell lines [66] enhances their invasion capacities by increasing expression of matrix metalloproteinase-1 and stimulating production of proangiogenic factors [52, 67]. Watanabe et al. showed that IL-1β produced by OC cells induced mesothelial cell β1-integrin-dependent peritoneal metastasis [68]. Increased levels of IL-1β found in the serum and/or the ascites of OC patients have been associated with decreased survival [69]. Likewise, IL-1β can effect OC progression by altering the expression of other proinflammatory cytokines, such as IL-6 which is a downstream target of IL-1β. IL-6 is known to play a major role in OC progression and prognosis and may also be a potential marker of immunological and metabolic changes in OC [70]. Elevated levels of IL-6 have been found in the serum and ascites of OC patients [71] and are also associated with poor prognosis [2]. In support of the data reported herein, we recently found that urinary levels of IL-1β were generally 5 times greater in women with OC compared to healthy controls [72]. Interestingly, while exact BRCA1 mutational status could not be determined, we also found that urinary levels of IL-1β were 3 times higher among women with benign ovarian disease and a FH of breast/ovarian cancer compared with women with benign ovarian disease and lacking a FH of breast/ovarian cancer. Likewise, OC patients with a confirmed FH of cancer had urinary IL-1β levels several fold higher than OC patients without a known FH of cancer. Therefore, chronic presence of IL-1β within the ovarian microenvironment may enhance malignant transformation and underscores the complexity among cancer cells within their microenvironment for tumor progression.

5. Conclusions

Our data identify the proinflammatory mediator, IL-1β, as a novel target in OSE cells expressing the 185delAG BRCA1 mutation. Further, the mechanism by which BRAT regulates IL-1β expression is twofold: (1) CREB-dependent transcriptional control and (2) caspase-1 cleavage of pro-IL-1β. It is interesting to speculate that increases in IL-1β might be limited to 185delAG rather than common to multiple BRCA1 mutations. While we have not been able to study other BRCA1 mutations in similar detail, a recent study by Rebeck et al. [73] suggests that differences in risk for breast and/or ovarian cancer may be linked to the locations of mutations in BRCA1 and BRCA2. Further, in prior publications, we have shown that targets downstream of 185delAG, including maspin, are unaffected when 185delAG is itself mutated to generate a further BRCA1 mutation [39] suggesting that the 185delAG BRCA1 mutation may promote tumorigenesis by a unique mechanism. Clearly, additional studies on the role of BRCA1 mutations to promote a chronic inflammatory phenotype are warranted since the potential also exists for IL-1β to serve as a predictor of OC and/or as a therapeutic target.

Conflict of Interests

The authors state that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported, in part, by a grant from the Ovarian Cancer Research Fund GRT 10935 (Patricia A. Kruk) and a National Sciences Foundation Florida-Georgia Louis Stokes for Alliance Minority Participation (FGLSAMP) Bridge to the Doctorate Award HRD no. 0929435 (Kamisha T. Woolery).

References

[1] ACS, Cancer Facts & Figures 2013, American Cancer Society, Atlanta, Ga, USA, 2013.
[2] N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung, "Ovarian surface epithelium: biology, endocrinology, and pathology," Endocrine Reviews, vol. 22, no. 2, pp. 255–288, 2001.
[3] R. J. Kurman and I.-M. Shih, "The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory," The American Journal of Surgical Pathology, vol. 34, no. 3, pp. 433–443, 2010.
[4] L. Dubeu, "The cell of origin of ovarian epithelial tumours," The Lancet Oncology, vol. 9, no. 12, pp. 1191–1197, 2008.
[5] M. P. Lux, P. A. Fasching, and M. W. Beckmann, "Hereditary breast and ovarian cancer: review and future perspectives," Journal of Molecular Medicine, vol. 84, no. 1, pp. 16–28, 2006.
[6] D. Ford, D. F. Easton, D. T. Bishop, S. A. Narod, and D. E. Goldgar, "Risks of cancer in BRCA1-mutation carriers," The Lancet, vol. 343, no. 8899, pp. 692–695, 1994.
[7] A. S. Whittemore, G. Gong, and J. Itnyre, "Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer," The American Journal of Human Genetics, vol. 60, no. 3, pp. 496–504, 1997.
[8] P. B. Mullan, J. E. Quinn, and D. P. Harkin, "The role of BRCA1 in transcriptional regulation and cell cycle control," Oncogene, vol. 25, no. 43, pp. 5854-5863, 2006.
[9] R. J. Linger and P. A. Kruk, “BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications,” The FEBS Journal, vol. 277, no. 15, pp. 3086–3096, 2010.

[10] J. M. Satagopan, J. Boyd, N. D. Kauff et al., “Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations,” Clinical Cancer Research, vol. 8, no. 2, pp. 3776–3781, 2002.

[11] N. C. Johnson and P. A. Kruk, “BRCA1 zinc RING finger domain disruption alters caspase response in ovarian surface epithelial cells,” Cancer Cell International, vol. 2, no. 1, article 7, 2002.

[12] N. C. Johnson, H. C. Dan, J. Q. Cheng, and P. A. Kruk, “BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells,” Experimental Cell Research, vol. 298, no. 1, pp. 9–16, 2004.

[13] J. D. O’Donnell, N. C. Johnson, T. D. Turbeville, M. Y. Alfonso, and P. A. Kruk, “BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells,” In Vitro Cellular & Developmental Biology—Animal, vol. 44, no. 8–9, pp. 357–367, 2008.

[14] P. Surowiak, V. Materna, M. Drag-Zalesinska et al., “Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cell lines and for ovarian cancer cases of longer survival rates,” International Journal of Gynecological Pathology, vol. 23, no. 2, pp. 131–139, 2006.

[15] E. O. Osterholtz, J. H. Johnson, and S. V. Nicosia, “An autodiagnostic study of rabbit ovarian surface epithelium before and after ovulation,” Biology of Reproduction, vol. 33, no. 3, pp. 729–738, 1985.

[16] N. Surowiak, V. Materna, M. Drag-Zalesinska et al., “Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cell lines and for ovarian cancer cases of longer survival rates,” International Journal of Gynecological Pathology, vol. 23, no. 2, pp. 131–139, 2006.

[17] H. Salazar, A. K. Godwin, M. B. Daly et al., “Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies,” Journal of the National Cancer Institute, vol. 88, no. 24, pp. 1810–1820, 1996.

[18] N. Auersperg, S. Maines-Bandiera, J. H. Booth, H. T. Lynch, A. K. Godwin, and T. C. Hamilton, “Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer,” American Journal of Obstetrics and Gynecology, vol. 173, no. 2, pp. 558–565, 1995.

[19] H. G. Dyck, T. C. Hamilton, A. K. Godwin, H. T. Lynch, S. Maines-Bandiera, and N. Auersperg, “Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer,” International Journal of Cancer, vol. 69, no. 6, pp. 429–436, 1996.

[20] R. B. Ness, J. A. Grissel, C. Cottreau et al., “Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer,” Epidemiology, vol. 11, no. 2, pp. 111–117, 2000.

[21] T. Suedinovong and M. E. Carney, “Current understanding of inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis,” Human Pathology, vol. 43, no. 11, pp. 1964–1972, 2012.

[22] C. Fuseya, A. Horiuchi, A. Hayashi et al., “Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis,” Human Pathology, vol. 43, no. 11, pp. 1964–1972, 2012.

[23] S. Ogawa, T. Kaku, S. Amada et al., “Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study,” Gynecologic Oncology, vol. 77, no. 2, pp. 298–304, 2000.

[24] H. Kobayashi, K. Sumimoto, N. Moniwa et al., “Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan,” International Journal of Gynecological Cancer, vol. 17, no. 1, pp. 37–43, 2007.

[25] A. Melin, P. Sparén, I. Persson, and A. Bergqvist, “Endometriosis and the risk of cancer with special emphasis on ovarian cancer,” Human Reproduction, vol. 21, no. 5, pp. 1237–1242, 2006.

[26] I. M. Zardawi, “Primary fallopian tube carcinoma arising in the setting of chronic pelvic inflammatory disease,” Case Reports in Medicine, vol. 2014, Article ID 645045, 7 pages, 2014.

[27] C. B. Rasmussen, M. T. Faber, A. Jensen et al., “Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors,” Cancer Causes & Control, vol. 24, no. 7, pp. 1459–1464, 2013.

[28] J. T. Casagrande, M. C. Pike, R. K. Ross, E. W. Louie, S. Roy, and B. E. Henderson, “Incessant ovulation and ovarian cancer,” The Lancet, vol. 314, no. 8135, pp. 170–173, 1979.

[29] H. O. Osterholzer, J. H. Johnson, and S. V. Nicosia, “An autodiagnostic study of rabbit ovarian surface epithelium before and after ovulation,” Biology of Reproduction, vol. 33, no. 3, pp. 729–738, 1985.

[30] S. V. Nicosia, R. J. Narconis, and B. O. Saunders, “Regulation and temporal sequence of surface epithelium morphogenesis in the postovulatory rabbit ovary,” Progress in Clinical and Biological Research, vol. 296, pp. 111–119, 1989.

[31] A. Macciò and C. Madeddu, “Inflammation and ovarian cancer,” Cytokine, vol. 58, no. 2, pp. 133–147, 2012.

[32] J. S. Fleming, C. R. Beaupl, I. Haviv, G. Chenevix-Trench, and O. L. Tan, “Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses,” Molecular and Cellular Endocrinology, vol. 247, no. 1-2, pp. 4–21, 2006.

[33] A. H. Lawal and C. B. Lynch, “Borderline ovarian cancer, bilateral surgical castration, chemotherapy and a normal delivery after ovum donation and in vitro fertilisation-embryo transfer,” British Journal of Obstetrics and Gynaecology, vol. 103, no. 9, pp. 931–932, 1996.

[34] J. Abbadou, E. Attieh, D. Atallah, A. Kessrouani, and G. Chaou, “Three cases of ovarian cancer after ovulation induction for infertility,” Contraception, Fertililité, Sexualité, vol. 25, no. 1, pp. 64–65, 1997.

[35] C. A. Dinarello, “Biologic basis for interleukin-1 in disease,” Blood, vol. 87, no. 6, pp. 2095–2147, 1996.

[36] C. V. Nicosia, R. J. Narconis, and B. O. Saunders, “Regulation and temporal sequence of surface epithelium morphogenesis in the postovulatory rabbit ovary,” Progress in Clinical and Biological Research, vol. 296, pp. 111–119, 1989.

[37] X. Messegueur, R. Escudero, D. Färre, O. Núñez, J. Martinez, and M. M. Albalà, “PROMO: detection of known transcription regulatory elements using species-tailored searches,” Bioinformatics, vol. 18, no. 2, pp. 333–341, 2002.

[38] D. Färre, R. Roset, M. Huerta et al., “Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN,” Nucleic Acids Research, vol. 31, no. 13, pp. 3651–3653, 2003.

[39] J. D. O’Donnell, R. J. Linger, and P. A. Kruk, “BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells,” Gynecologic Oncology, vol. 116, no. 2, pp. 262–268, 2010.

[40] B. C. Vanderhyden, T. J. Shaw, and J. F. Ether, “Animal models of ovarian cancer,” Reproductive Biology and Endocrinology, vol. 1, article 67, 2003.

[41] F. Jiang, B. O. Saunders, E. Haller, S. Livingston, S. V. Nicosia, and W. Bai, “Conditionally immortal ovarian cell lines for investigating the influence of ovarian stroma on the estrogen sensitivity and tumorigenicity of ovarian surface epithelial...
cells,” *In Vitro Cellular and Developmental Biology Animal*, vol. 39, no. 7, pp. 304–312, 2003.

[42] C. H. Holschneider and J. S. Berek, “Ovarian cancer: epidemiology, biology, and prognostic factors,” *Seminars in Surgical Oncology*, vol. 19, no. 1, pp. 3–10, 2000.

[43] C. M. Counter, H. W. Hirte, S. Bacchetti, and C. B. Harley, “Telomerase activity in human ovarian carcinoma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 8, pp. 2900–2904, 1994.

[44] S. J. Ramus and S. A. Gayther, “The contribution of BRCA1 and BRCA2 to ovarian cancer,” *Molecular Oncology*, vol. 3, no. 2, pp. 138–150, 2009.

[45] L. Perrin-Vidoz, O. M. Sinilnikova, D. Stoppa-Lyonnet, G. M. Lenoir, and S. Mazoyer, “The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons,” *Human Molecular Genetics*, vol. 11, no. 23, pp. 2805–2814, 2002.

[46] V. Sylvain, S. Lafarge, and Y.-J. Bignon, “Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemo sensitivity in a mouse ovarian cancer cell line,” *International Journal of Oncology*, vol. 20, no. 4, pp. 845–853, 2002.

[47] M. Thangaraju, S. H. Kaufmann, and F. J. Couch, “BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines,” *The Journal of Biological Chemistry*, vol. 275, no. 43, pp. 33487–33496, 2000.

[48] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” *Cell*, vol. 140, no. 6, pp. 883–899, 2010.

[49] M.-K. Kim, K. Kim, J. Y. Han, J. M. Lim, and Y. S. Song, “Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer,” *Genes and Nutrition*, vol. 6, no. 2, pp. 109–115, 2011.

[50] S. S. Seo, Y. S. Song, D.-H. Kang et al., “Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer,” *Gynecologic Oncology*, vol. 92, no. 3, pp. 927–935, 2004.

[51] T. V. Clendenen, E. Lundin, A. Zeleniuch-Jacquotte et al., “Circulating inflammation markers and risk of epithelial ovarian cancer,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 20, no. 5, pp. 799–810, 2011.

[52] C. Denkert, I. Koch, S. Berger, M. Köbel, A. Siegert, and S. Hauptmann, “Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells,” *Cancer Letters*, vol. 195, no. 1, pp. 101–109, 2003.

[53] A. Yella, P. Bitterman, S. Sharma et al., “Interleukin 16 expression changes in association with ovarian malignant transformation,” *The American Journal of Obstetrics and Gynecology*, vol. 210, no. 3, pp. 272.e1–272.e10, 2014.

[54] L. Baandrup, M. T. Faber, U. J. Christensen et al., “Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 92, no. 3, pp. 245–255, 2013.

[55] M. A. Murphy, B. Trabert, H. P. Yang et al., “Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review,” *Cancer Causes & Control*, vol. 23, no. 11, pp. 1839–1852, 2012.

[56] K. D. Crew and A. I. Neugut, “Aspirin and NSAIDs: effects in breast and ovarian cancers,” *Current Opinion in Obstetrics and Gynecology*, vol. 18, no. 1, pp. 71–75, 2006.

[57] S. S. Chen, A. Michael, and S. A. Butler-Manuel, “Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals,” *Discovery Medicine*, vol. 13, no. 68, pp. 7–17, 2012.

[58] S. Chen, M. Cooper, M. Jones et al., “Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals,” *Cell Biology and Toxicology*, vol. 27, no. 2, pp. 133–147, 2011.

[59] H. Luo, M. K. Daddysman, G. O. Rankin, B.-H. Jiang, and Y. C. Chen, “Kaempferol enhances cisplatin’s effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc,” *Cancer Cell International*, vol. 10, article 16, 2010.

[60] H. Luo, B.-H. Jiang, S. M. King, and Y. C. Chen, “Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids,” *Nutrition and Cancer*, vol. 60, no. 6, pp. 800–809, 2008.

[61] J. H. Seo, K. J. Jeong, W. J. Oh et al., “Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin,” *Cancer Letters*, vol. 288, no. 1, pp. 50–56, 2010.

[62] C. A. Dinarello, A. Simon, and J. W. M. van der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” *Nature Reviews Drug Discovery*, vol. 11, no. 8, pp. 633–652, 2012.

[63] J.-H. Kim, C.-H. Yu, J.-Y. Yhee, K.-S. Im, and J.-H. Sur, “Lymphocyte infiltration, expression of interleukin (IL) -1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours,” *Journal of Comparative Pathology*, vol. 142, no. 2-3, pp. 177–186, 2010.

[64] I. G. Schauer, J. Zhang, Z. Xing et al., “Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts,” *Neoplasia*, vol. 15, no. 4, pp. 409–420, 2013.

[65] C. A. Dinarello, “The paradox of pro-inflammatory cytokines in cancer,” *Cancer and Metastasis Reviews*, vol. 25, no. 3, pp. 307–313, 2006.

[66] A. M. Lewis, S. Varghese, H. Xu, and H. R. Alexander, “Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment,” *Journal of Translational Medicine*, vol. 4, article 48, 2006.

[67] S. Stadlmann, A. Amberger, J. Pollheimer et al., “Ovarian carcinoma cells and IL-1β-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions,” *Gynecologic Oncology*, vol. 97, no. 3, pp. 784–789, 2005.

[68] T. Watanabe, T. Hashimoto, T. Sugino et al., “Production of cMyc,” *Kaempferol enhances cisplatin’s effect on ovarian cancer cell lines*.

[69] A. Musseau, C. Pirvulescu, D. Könsger et al., “Decreased IL-1β and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours,” *Journal of Comparative Pathology*, vol. 142, no. 2-3, pp. 177–186, 2010.

[70] A. Mustea, C. Pirvulescu, D. Könsger et al., “Decreased IL-1α concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer,” *Cytokine*, vol. 42, no. 1, pp. 77–84, 2008.

[71] A. Macciò and C. Madeddu, “The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications—a review,” *Journal of Molecular Medicine*, vol. 91, no. 12, pp. 1355–1368, 2013.

[72] M. M. Moradi, L. F. Carson, J. B. Weinberg, A. F. Haney, L. B. Twiggs, and S. Ramakrishnan, “Serum and ascitic fluid levels of
interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer,” *Cancer*, vol. 72, no. 8, pp. 2433–2440, 1993.

[72] K. T. Woolery, M. S. Hoffman, J. Kraft, S. V. Nicosia, A. Kumar, and P. A. Kruk, “Urinary interleukin-1β levels among gynecological patients,” *Journal of Ovarian Research*, vol. 7, article 104, 2014.

[73] T. R. Rebbeck, N. Mitra, F. Wan et al., “Association of type and location of *BRCA1* and *BRCA2* mutations with risk of breast and ovarian cancer,” *The Journal of the American Medical Association*, vol. 313, no. 13, pp. 1347–1361, 2015.